{'text': 'European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS', 'publisher': {'href': 'https://investors.biogen.com', 'title': 'Biogen | Investor Relations'}, 'created_at': 'Fri, 27 Mar 2015 07:00:00 GMT', 'description': 'European Medicines Agency Validates Marketing Authorisation Application for ZINBRYTA™ (Daclizumab High-Yield Process) for Treatment of MS  Biogen | Investor Relations', 'url': 'https://news.google.com/rss/articles/CBMiwAFBVV95cUxQOTlQZDJjTUplcXNEVVNuNklqZjhTZHdYeE5qeDdzYW1fbzJ0Y3NYZkZUUEJ2NDhmNDJkS1VrWkRPY0dqRWgxQ2cwVzVHTnNTUldSSjZqeFQ3ekRQY3dQeTR4d181N2JVWEk0MGUtbVBZWk40MGczcUZRY0cySE5jTmpOU29rVzhaeWprREROVDVaT2dYMlY3R05Bb2ZuTWgtVXV0YnNFbi1VUGNnUWo2Vm12NExZdDVmRVNrS0ljR0g?oc=5&hl=en-US&gl=US&ceid=US:en'}
